Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Angiodynamics (ANGO) over the last 16 years, with Q4 2025 value amounting to -$238000.0.

  • Angiodynamics' Gains from Investment Securities fell 1200000.0% to -$238000.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $417000.0, marking a year-over-year increase of 11060.61%. This contributed to the annual value of $800000.0 for FY2025, which is 7582.42% up from last year.
  • Latest data reveals that Angiodynamics reported Gains from Investment Securities of -$238000.0 as of Q4 2025, which was down 1200000.0% from -$264000.0 recorded in Q3 2025.
  • Over the past 5 years, Angiodynamics' Gains from Investment Securities peaked at $2.0 million during Q2 2023, and registered a low of -$299000.0 during Q1 2024.
  • Moreover, its 5-year median value for Gains from Investment Securities was $146500.0 (2021), whereas its average is $355650.0.
  • As far as peak fluctuations go, Angiodynamics' Gains from Investment Securities surged by 62256.1% in 2022, and later tumbled by 1200000.0% in 2025.
  • Angiodynamics' Gains from Investment Securities (Quarter) stood at $609000.0 in 2021, then skyrocketed by 170.28% to $1.6 million in 2022, then tumbled by 92.16% to $129000.0 in 2023, then crashed by 98.45% to $2000.0 in 2024, then tumbled by 12000.0% to -$238000.0 in 2025.
  • Its last three reported values are -$238000.0 in Q4 2025, -$264000.0 for Q3 2025, and $949000.0 during Q2 2025.